Enhertu (fam-trastuzumab deruxtecan-nxki) has received FDA approval for HR-positive, HER2-low, HER2-ultralow metastatic breast cancer.

ENHERTU (5.4 mg/kg) is approved in more than 65 countries worldwide for the treatment of adult patients with unresectable or metastatic HER2 low (IHC 1+ or IHC 2+/ISH-) breast cancer who have ...

A study published by Caris showed that certain tumor types had very low or no HER2 overexpression, which has implications for biomarker testing strategies.

ENHERTU® Approved in the U.S. as First HER2 Directed Therapy for Patients with HER2 Low or HER2 Ultralow Metastatic Breast Cancer Following Disease Progression After One or More Endocrine Therapies ...

The FDA will speed up their review of Enhertu for HR-positive, HER2-low/ultralow advanced breast cancer that cannot be removed via surgery.

AstraZeneca and Daiichi Sankyo’ s ENHERTU ® has been approved in the US for the treatment of adult patients with unresectable or metastatic hormone receptor- positive, HER2-low or HER2-ultralow ...

ENHERTU (5.4 mg/kg) is approved in more than 30 countries for the treatment of adult patients with unresectable or metastatic hormone receptor (HR) positive, HER2 low (IHC 1+ or IHC 2+/ISH-) or ...

ENHERTU (5.4 mg/kg) is approved in more than 80 countries worldwide for the treatment of adult patients with unresectable or metastatic HER2 low (IHC 1+ or IHC 2+/ISH-) breast cancer who have ...

Roche gets the first FDA approval for a diagnostic test for HER2-ultralow breast cancer, now on the label of AstraZeneca and Daiichi Sankyo's Enhertu.

Thousands of women battling advanced breast cancer could be denied access to crucial life-extending medication due to an "unfair" assessment process for NHS drug approval. At such a critical moment in ...

Inavolisib (Itovebi) is a new targeted therapy for HR+ HER2-negative metastatic breast cancer with a PIK3CA mutation.

TOKYO & BASKING RIDGE, N.J., January 27, 2025--ENHERTU Approved in the U.S. as First HER2 Directed Therapy for HER2 Low or HER2 Ultralow mBC Following Disease Progression After Endocrine Therapy ...